HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth

Cell Host Microbe. 2018 Oct 10;24(4):593-599.e3. doi: 10.1016/j.chom.2018.09.001. Epub 2018 Sep 27.

Abstract

Eliciting antibodies that neutralize a broad range of circulating HIV strains (broadly neutralizing antibodies [bnAbs]) represents a key priority for vaccine development. HIV superinfection (re-infection with a second strain following an established infection) has been associated with neutralization breadth, and can provide insights into how the immune system responds to sequential exposure to distinct HIV envelope glycoproteins (Env). Characterizing the neutralizing antibody (nAb) responses in four superinfected women revealed that superinfection does not boost memory nAb responses primed by the first infection or promote nAb responses to epitopes conserved in both infecting viruses. While one superinfected individual developed potent bnAbs, superinfection was likely not the driver as the nAb response did not target an epitope conserved in both viruses. Rather, sequential exposure led to nAbs specific to each Env but did not promote bnAb development. Thus, sequential immunization with heterologous Envs may not be sufficient to focus the immune response onto conserved epitopes.

Keywords: HIV; antibodies; broadly neutralizing antibodies; superinfection; vaccines.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antibodies, Neutralizing / immunology
  • Female
  • HEK293 Cells
  • HIV Antibodies / immunology*
  • HIV Envelope Protein gp120 / genetics
  • HIV Envelope Protein gp120 / immunology
  • HIV Infections / blood
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • Humans
  • Middle Aged
  • Peptide Fragments / genetics
  • Peptide Fragments / immunology
  • RNA, Viral / blood
  • RNA, Viral / genetics
  • RNA, Viral / immunology*
  • Superinfection / blood
  • Superinfection / complications
  • Superinfection / drug therapy
  • Superinfection / virology*
  • Tenofovir / therapeutic use

Substances

  • Anti-HIV Agents
  • Antibodies, Neutralizing
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • HIV envelope protein gp120 (305-321)
  • Peptide Fragments
  • RNA, Viral
  • Tenofovir